A new virus outbreak can transform from an isolated clinical concern into a major operational and financial crisis remarkably quickly.
- Patients need to be identified.
- Healthcare workers require protection.
- Samples need to be collected and analysed.
- Isolation areas may be needed.
- Contacts may need tracing.
- Additional cleaning and decontamination can become necessary.
- Beds can remain occupied for longer, all while wards or procedures may be restricted.
And that is before considering the wider economic effects of an outbreak.
The COVID-19 pandemic showed us what can happen when a new virus emerges on a global scale.
But healthcare facilities do not need another pandemic to experience the financial consequences of an infectious-disease outbreak. Local outbreaks involving respiratory viruses, gastrointestinal pathogens, drug-resistant bacteria or emerging fungal pathogens can also place substantial pressure on hospital resources.
This makes diagnostic preparedness worth considering as an investment rather than simply an expense.
The World Health Organization (WHO) describes diagnostics as fundamental to identifying pathogens and successfully containing and controlling infectious-disease outbreaks. It also estimates that diagnostic results influence approximately 70% of healthcare decisions, despite diagnostic services accounting for only around 3–5% of healthcare budgets.

For hospitals and laboratories across Africa, the question may therefore be changing.
Instead of asking:
“Can we justify investing in molecular diagnostics today?”
Healthcare decision-makers might also consider:
“What could it cost us if an outbreak occurs and we do not have sufficient diagnostic capacity?”
This article examines that question, including what a Candida auris outbreak can teach us about the potentially enormous visible and hidden costs of infectious-disease outbreaks.
Important distinction: Candida auris is a fungus, not a virus. The example is used in this article because Bosch has published detailed estimates of the institutional cost of a C. auris outbreak and because it illustrates the wider economic principle behind outbreak preparedness. The Bosch Vivalytic device in this article cannot automatically detect an unknown new virus; and so a validated assay for the relevant pathogen is required.
Why Rapid Laboratory Detection Matters During a New Virus Outbreak
Outbreak control depends heavily on information as Healthcare professionals need to establish a lot of info including:
- What pathogen is circulating?
- Who is infected?
- Where are infections occurring?
- Is transmission taking place inside the healthcare facility?
- Are cases connected?
- Which patients require isolation?
- Are infection-control measures working?
And so much more!
Without laboratory information, many of those decisions become considerably harder. Public-health laboratories are a cornerstone of health-emergency alert and response systems, that provide information required to detect, confirm and monitor epidemic and pandemic events.
Africa CDS’s 2026 guidance on decentralising laboratory capacity warns that heavily centralised testing systems can delay case confirmation and timely intervention, particularly in rural and difficult-to-reach areas. That is why strengthening laboratory capacity closer to where outbreaks occur is therefore an important component of epidemic preparedness.
This becomes particularly relevant for hospitals that currently need to send molecular samples elsewhere.
So the issue then may not be whether an external reference laboratory can perform the test, but:
How long it takes to get the sample there and receive an actionable result.

The Real Cost of an Outbreak Can Be Much Larger Than the Cost of Testing.
Healthcare procurement understandably focuses on price.
- How much does an analyser cost?
- How much does each cartridge cost?
- What does maintenance cost?
- How many tests will the laboratory perform?
We fully understand that those are necessary questions, but they only focus on one side of the financial equation.
An outbreak has costs too. And many of those costs do not appear in a hospital’s normal laboratory budget.
Bosch’s outbreak analysis describes them rather effectively as:
“The costs that aren’t planned in any budget.”
They can include additional staffing, isolation, cleaning, decontamination, longer hospital stays, occupied beds, cancelled procedures and temporary ward closures.
Beyond these direct costs sit potentially much larger losses from operational downtime and reputational damage.
That means the cost of diagnostic preparedness should ideally be compared not only with today’s laboratory budget, but also with the risk-adjusted cost of delayed detection and outbreak disruption.
Case Study: What Can a Virus Outbreak Cost a Hospital?

The Bosch brochure supplied to MediDiagAfrica provides an interesting example involving Candida auris.
The C. auris is not a virus, but an emerging fungal pathogen associated particularly with healthcare environments.
But that does not make the example any less useful.
Bosch’s model estimates the following:
| Potential Outbreak Impact | Bosch Modelled Estimate |
|---|---|
| Additional staff workload | ~175 hours per case |
| Hygiene measures | ~€11,000 per case |
| Additional hospital stay | ~53 days per patient |
| Total financial impact | ~€115,000 per case |

These are striking numbers, but they require context.
Bosch states that its estimates are based on a 100-bed surgical setting, German reimbursement data, a 60-day length-of-stay assumption drawn from outbreak reports and scientific literature, and a six-month outbreak duration.
- They should therefore not be presented as the expected cost of every C. auris case or transferred directly to hospitals in Cameroon, Nigeria, Kenya or elsewhere in Africa.
The underlying economic lesson, however, travels much better than the precise euro figure.
Outbreaks consume resources, and those resources extend far beyond the diagnostic test itself.
1. 175 Additional Staff Hours Per Case
An easy cost to underestimate is staff time.
Bosch’s model above associates management of an outbreak with approximately 175 hours of additional staff workload per case.
Think about what an outbreak can require for a quick second.
- Patients may need isolation.
- Staff may require additional infection-control procedures.
- Contacts may need investigation and samples have to be collected.
- Rooms need cleaning.
- Results need to be communicated.
- Meetings may be required between microbiology, infection prevention, nursing, clinical and hospital-management teams.
None of the above happens without people.
And healthcare workers dealing with an outbreak are generally the same professionals who already have other responsibilities.
The financial cost therefore includes an opportunity cost, i,e. What normal work is delayed because staff are managing the outbreak?
2. Hygiene and Decontamination Can Be Expensive

Infection control also consumes materials and labour.
Bosch estimates hygiene costs in its C. auris scenario at approximately €11,000 per case, which reflects the intensive decontamination and isolation measures that can be necessary.
Again, this is not a universal cost figure.
Different pathogens require different infection-control measures, and costs vary dramatically between healthcare systems, but every healthcare administrator can understand the underlying principle.
An uncontrolled infectious-disease event can suddenly create demand for:
- additional PPE, isolation capacity, cleaning staff, disinfectants, specialist decontamination, additional testing and greater infection-control staffing, etc.
- In comparison, a small diagnostic budget can begin to look very different when compared with the cost of containing an outbreak.
3. An Outbreak Can Consume Valuable Hospital Beds

The Bosch model also associates each infection with approximately 53 additional days of hospital stay.
A bed that is occupied for longer than necessary has two costs.
- The first is the direct cost of caring for that patient.
- The second is the patient who cannot use that bed.
This is particularly significant where hospitals already operate near capacity.
The financial consequence of an outbreak therefore cannot always be measured simply by adding up consumables and staff hours.
There is also lost capacity.
4. The €115,000 Figure May Still Not Represent the Biggest Cost

Perhaps the most interesting part of Bosch’s analysis appears after its estimated €115,000 total cost per case.
The brochure highlights three wider consequences:
- ward closure
- loss of revenue
- and damage to reputation.
This is the financial iceberg.
And if an outbreak becomes publicly associated with a particular healthcare facility, patient confidence can also suffer.
That is why Bosch argues that revenue lost through weeks of downtime can potentially exceed the direct costs of the outbreak itself, and that is a much broader way to evaluate investment in diagnostics.
Where Exactly Does Molecular Diagnostics Fit Into New Virus Outbreak Preparedness?
PCR and other molecular technologies can detect genetic material associated with pathogens.
- When a validated assay exists, this can provide highly specific information relatively quickly.
- During an outbreak, that information may help healthcare professionals identify cases, investigate clusters, support surveillance and make infection-control decisions.
But there is an important limitation.
A Molecular Diagnostic Device Cannot Predict the Next Virus
WHO’s R&D Blueprint recognises precisely this challenge. During emerging health emergencies, research networks may need to accelerate the development of diagnostics, vaccines and medicines appropriate to the newly identified threat.
So investing in molecular diagnostics is not the same as buying universal protection against the next pandemic.
- The real advantage is preparedness and capability.
The Laboratory That Has Molecular Capability Already Starts From a Different Position

Consider two hospitals.
- Hospital A has little molecular diagnostic capability.
- Hospital B already performs routine PCR testing, has trained personnel, established specimen-handling procedures, infection-control relationships and experience operating molecular diagnostic equipment.
Neither hospital automatically possesses a test for a completely unknown virus.
But when an appropriate validated assay eventually becomes available, Hospital B may have fewer infrastructure and workflow barriers to overcome.
This is the less visible benefit of investing in diagnostics before an emergency.
You are not only buying today’s tests, but you may also be developing:
- Laboratory experience,
- Trained staff,
- molecular-testing workflows,
- quality processes,
- sample-handling capability
- and an organisational culture accustomed to using diagnostic information.
Why a Multi-Purpose Molecular Platform Can Change the Investment Calculation
This brings us to an important consideration when evaluating a molecular diagnostic device such as Bosch Vivalytic.
A hospital does not need to purchase the platform and leave it unused while waiting for the next outbreak.
Vivalytic already supports molecular testing across several established infectious-disease areas.
The current portfolio includes applications associated with:
| Diagnostic Area | Examples within the Vivalytic Portfolio |
|---|---|
| Respiratory infections | SARS-CoV-2, Influenza A/B, RSV, Bordetella |
| Gastrointestinal infections | Norovirus, Rotavirus, C. difficile |
| Healthcare-associated infections | MRSA/SA, Candida auris |
| Sexually transmitted infections | Multiplex STI testing, Mycoplasma/Ureaplasma |
| Neurological infections | Bacterial meningitis |
This is an important distinction.
The investment case does not have to be:
“Buy an analyser today in case an unknown virus appears someday.”
A much more rational question is:
“Can this platform address diagnostic requirements we have today while also strengthening our molecular-testing capability for future infectious-disease challenges?”
That is a considerably stronger procurement argument.
Prevention – When Does Diagnostic Investment Make Sense?

There is no universal answer.
Not every hospital needs the same molecular platform.
A small clinic with low infectious-disease testing volumes will have a different business case from a tertiary hospital, private diagnostic laboratory or regional referral centre.
But procurement teams can compare two broad categories of cost.
| Planned Diagnostic Investment | Potential Unplanned Outbreak Costs |
|---|---|
| Molecular analyser | Additional staff hours |
| Test cartridges | Isolation facilities |
| Staff training | PPE and infection-control consumables |
| Maintenance | Decontamination |
| Quality assurance | Extended patient stays |
| Consumables | Occupied beds |
| Technical support | Ward closures |
| Supply-chain planning | Cancelled procedures |
| Routine testing | Lost revenue |
| Preventive screening where appropriate | Reputational damage |
- The left-hand column is largely planned.
- The right-hand column can arrive suddenly.
That does not automatically make every molecular diagnostic purchase cost-effective, it just simply demonstrates why investment in analytical diagnostics purely as an additional laboratory expense can produce an incomplete financial picture.
What Should Hospitals Do When Reports of a “New Virus Outbreak” Appear?

Search engines and social media can make an emerging outbreak appear closer or more certain than it really is.
That is why Healthcare organisations should avoid reacting to headlines alone.
- When reports of a new virus outbreak appear, decision-makers should first establish whether the event has been confirmed by recognised public-health authorities.
Useful authoritative resources include the WHO Health Emergencies programme and the WHO African Region Health Emergency Information Hub.
WHO’s outbreak system monitors and verifies potential public-health threats, while the African regional platform provides outbreak and emergency information relevant to the continent.
For healthcare institutions, the practical questions then become:
- Has the pathogen actually been identified?
- Is there evidence of local or regional transmission?
- What case definition is being used?
- What specimens are required?
- Is a validated diagnostic assay available?
- Can the existing laboratory perform it?
- If not, where should specimens be referred?
- How quickly can results be obtained?
- What biosafety requirements apply?
- What infection-prevention measures are recommended?
- Is additional screening appropriate?
- Do staff require new training?
- Are sufficient consumables and PPE available?
- How will positive results be communicated and escalated?
This approach helps distinguish preparedness from panic.
Could Molecular Diagnostics Actually Save a Hospital Money?
Potentially.
But this should be assessed institution by institution. The appropriate calculation is not simply:
Purchase price ÷ number of tests.
A more complete economic assessment could consider:
Current external laboratory expenditure
- sample transportation costs
- staff time
- current turnaround times
- patient recall or follow-up costs
- potential bed-day savings
- possible infection-control benefits
- outbreak-related operational risk
- revenue protected by avoiding unnecessary downtime
against:
equipment + cartridges + training + maintenance + quality assurance + staffing + infrastructure + support.
This creates a much more realistic business case.
- For some institutions, the numbers may support local molecular diagnostics.
- For others, referral to a central laboratory may remain more economical.
The purpose of an assessment should be to determine which is true.
Is Your Hospital, Clinic or Lab Prepared for the Next Infectious-Disease Outbreak?

Healthcare organisations cannot know exactly what the next major outbreak will be. They can only assess how prepared they are to respond.
For hospital administrators, laboratory managers, microbiologists, infection-control professionals and procurement teams, that means looking beyond individual tests and asking broader questions about diagnostic resilience.
- How quickly can your laboratory identify the pathogens it already encounters?
- Which samples currently need to leave your facility?
- How quickly could your organisation respond to an outbreak involving a supported pathogen?
- And could a molecular diagnostic platform serve your routine testing requirements while strengthening that preparedness?
MediDiagAfrica can help healthcare organisations explore the Bosch Vivalytic molecular diagnostic device, its available test portfolio and how its capabilities may fit existing laboratory requirements.
You can:
Request information about Bosch Vivalytic
Discuss your hospital’s molecular diagnostic requirements
Request a Vivalytic demonstration
Explore which Vivalytic assays may be relevant to your facility
Enquire about availability in your country
Individual Vivalytic products are not available in every region, and assay availability, regulatory status and intended use should always be confirmed for the relevant market before procurement.
This article is intended for healthcare and laboratory professionals and provides general educational and product information. It does not constitute medical advice, outbreak guidance or a guarantee that molecular testing will prevent an outbreak or produce financial savings. Healthcare organisations should follow WHO, national public-health authority, infection-control and applicable regulatory guidance.
